Treatment of primary spontaneous pneumothorax in adults - UpToDate
Treatment of primary spontaneous pneumothorax in adults
Treatment of primary spontaneous pneumothorax in adults
Author:
YC Gary Lee, MBChB, PhD
Section Editor:
V Courtney Broaddus, MD
Deputy Editor:
Geraldine Finlay, MD
Literature review current through: Mar 2024.
This topic last updated: Mar 07, 2024.

INTRODUCTION

Gas in the pleural space is termed pneumothorax. Pneumothorax can be a life-threatening condition that needs prompt attention. The management strategies of primary spontaneous pneumothorax (PSP; presents in the absence of an external factor/underlying cause) and secondary spontaneous pneumothorax (SSP; presents as a complication of underlying lung disease) (table 1) differ in their management strategies.

The management of PSP is discussed in this topic review. The etiology and diagnosis of pneumothorax and the management of SSP are discussed separately. (See "Pneumothorax in adults: Epidemiology and etiology" and "Clinical presentation and diagnosis of pneumothorax" and "Treatment of secondary spontaneous pneumothorax in adults".)

INITIAL EVALUATION AND MANAGEMENT

General principles — Following the radiographic identification of PSP, clinicians should quickly estimate the stability of the patient and the symptom burden so that appropriate therapy can be initiated. The principle focus of PSP management is to relieve symptoms and stop the air leak rather than rapidly expanding the lung to achieve radiographic resolution (ie, "treating the chest radiograph"), which does not necessarily stop the air leak. The assessment of size, while reasonable, is now less important in determining a treatment strategy. Size assessment is discussed separately. (See "Clinical presentation and diagnosis of pneumothorax", section on 'Pneumothorax size'.)

The approach to managing PSP varies widely among institutions and across continents. Our approach expands upon that outlined in several published clinical consensus statements and guidelines from the American College of Chest Physicians (ACCP; 2001), the British Thoracic Society (BTS; 2023), the European Respiratory Society (2015), and the Japanese Association for Chest Surgery (2014) [1-4]. Our approach is one that prioritizes patient safety and symptom control, preferably with minimal intervention, to avoid associated pain and risks.

Symptom control — All patients with PSP should receive resuscitation with a focus on airway stabilization (if needed), supplemental oxygen to treat hypoxemia (if present), and the provision of adequate analgesia (if indicated). PSP is rarely life-threatening, and the associated breathlessness is typically mild, often only affecting severe exertion; some patients may also experience pain. The clinical features of pneumothorax are described separately. (See "Clinical presentation and diagnosis of pneumothorax", section on 'Clinical presentation'.)

Disclaimer: This generalized information is a limited summary of diagnosis, treatment, and/or medication information. It is not meant to be comprehensive and should be used as a tool to help the user understand and/or assess potential diagnostic and treatment options. It does NOT include all information about conditions, treatments, medications, side effects, or risks that may apply to a specific patient. It is not intended to be medical advice or a substitute for the medical advice, diagnosis, or treatment of a health care provider based on the health care provider's examination and assessment of a patient's specific and unique circumstances. Patients must speak with a health care provider for complete information about their health, medical questions, and treatment options, including any risks or benefits regarding use of medications. This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient. UpToDate, Inc. and its affiliates disclaim any warranty or liability relating to this information or the use thereof. The use of this information is governed by the Terms of Use, available at https://www.wolterskluwer.com/en/know/clinical-effectiveness-terms. 2024© UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.
Loading
Please wait